Biogen Inc BIIB:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
290.65 -9.01   -3.01%1,567,5261.3M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 10/21/2016 (03:59 PM 10/21/2016 Eastern Standard Time)

Latest News Headlines for Biogen Inc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of a Class Action Lawsuit -- BIIB

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of a Class Action Lawsuit -- BIIB NEW YORK, Oct. 21, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:

How These Biotech Stocks are Faring? -- Biogen, Juno Therapeutics, Regeneron Pharma, and ProNAi Therapeutics

NEW YORK, October 18, 2016 /PRNewswire/ -- Ahead of today's trading session, takes a closer look at four Biotech equities, namely: Biogen Inc. (NASDAQ: BIIB), Juno Therapeutics Inc. (NASDAQ: JUNO), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), and ProNAi Therapeutics Inc. (NASDAQ: DNAI). According to IBISWorld's May 2016 market research report, the global biotechnology industry's contribution to the overall global economy is expected to grow 3.5% per year on average during the ten years to 2021 - slightly higher than the annualized global GDP growth of 2.7% over the same period. Register now and get full and free access to our downloadable research reports on these stocks at:

View more recent headlines

Peers Information HelpBIIB Biogen Inc vs. Peers

Biogen Inc
Shire PLC (ADR)
Novo Nordisk A/S (ADR)
Abbott Laboratories
Allergan plc
Biogen Inc
Shire PLC (ADR)
Novo Nordisk A/S (ADR)
Abbott Laboratories
Allergan plc
Biogen Inc
Shire PLC (ADR)
Novo Nordisk A/S (ADR)
Abbott Laboratories
Allergan plc
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings

This report contains detailed information about the company's business finances and management.


Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.


collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open299.07
Previous Close290.65
Day High299.07
Day Low289.78
52 Week High8/2/2016 | 333.65
52 Week Low6/27/2016 | 223.0211
% Off 52 Week High-12.89%
% Off 52 Week Low30.32%
Beta (5 Yr)0.7
Volatility Avg10/21/2016 | 34.41
10-Day Avg. Volume1,345,014
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2016 | 17.13
P/E Ratio6/30/2016 | 17.0
Market CapLarge Cap | 63.7B
Shares Outstanding219.12M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

expand, down-facing arrow indicating expanded view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short2.45M
Short Ratio1.9
Short % of Float1.12%
As of 9/30/2016
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.